Chimerix Toekomstige groei

Future criteriumcontroles 2/6

Chimerix is forecast to grow earnings and revenue by 29.9% and 60.7% per annum respectively while EPS is expected to grow by 37.1% per annum.

Belangrijke informatie

29.9%

Groei van de winst

37.1%

Groei van de winst per aandeel

Biotechs winstgroei	27.1%
Inkomstengroei	60.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Winst- en omzetgroeiprognoses

NasdaqGM:CMRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	34	-85	-80	-96	5
12/31/2025	2	-92	-94	-95	5
12/31/2024	6	-86	-94	-77	5
6/30/2024	0	-85	-68	-68	N/A
3/31/2024	0	-83	-64	-64	N/A
12/31/2023	0	-82	-69	-69	N/A
9/30/2023	1	-85	-75	-74	N/A
6/30/2023	34	180	-50	-49	N/A
3/31/2023	34	176	-46	-46	N/A
12/31/2022	34	172	-47	-47	N/A
9/30/2022	33	154	-61	-61	N/A
6/30/2022	1	-106	-83	-83	N/A
3/31/2022	1	-101	-86	-85	N/A
12/31/2021	2	-173	-100	-100	N/A
9/30/2021	3	-145	-75	-75	N/A
6/30/2021	5	-138	-68	-68	N/A
3/31/2021	6	-131	-63	-63	N/A
12/31/2020	5	-44	-36	-36	N/A
9/30/2020	11	-35	-31	-30	N/A
6/30/2020	11	-98	-64	-64	N/A
3/31/2020	11	-105	-70	-70	N/A
12/31/2019	13	-113	-75	-75	N/A
9/30/2019	11	-124	-80	-80	N/A
6/30/2019	9	-66	-51	-51	N/A
3/31/2019	9	-67	-51	-51	N/A
12/31/2018	7	-69	-54	-54	N/A
9/30/2018	4	-74	-58	-58	N/A
6/30/2018	5	-75	-56	-56	N/A
3/31/2018	4	-73	N/A	-55	N/A
12/31/2017	4	-71	N/A	-50	N/A
9/30/2017	5	-67	N/A	-48	N/A
6/30/2017	4	-66	N/A	-49	N/A
3/31/2017	6	-68	N/A	-49	N/A
12/31/2016	6	-76	N/A	-64	N/A
9/30/2016	7	-99	N/A	-87	N/A
6/30/2016	8	-115	N/A	-99	N/A
3/31/2016	11	-121	N/A	-110	N/A
12/31/2015	11	-117	N/A	-100	N/A
9/30/2015	9	-100	N/A	-84	N/A
6/30/2015	8	-84	N/A	-70	N/A
3/31/2015	4	-71	N/A	-57	N/A
12/31/2014	4	-59	N/A	-47	N/A
9/30/2014	4	-47	N/A	-37	N/A
6/30/2014	3	-37	N/A	-31	N/A
3/31/2014	3	-46	N/A	-29	N/A
12/31/2013	4	-71	N/A	-26	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: CMRX is forecast to remain unprofitable over the next 3 years.

Winst versus markt: CMRX is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: CMRX is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: CMRX's revenue (60.7% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: CMRX's revenue (60.7% per year) is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time

Chimerix Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 36%

Price target decreased by 8.7% to US$7.00

Consensus revenue estimates fall by 22%

Consensus revenue estimates decrease by 48%, EPS upgraded

Price target decreased by 8.3% to US$7.33

Price target decreased to US$8.00

Recent updates

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Chimerix: Searching For Clarity

Forecast to breakeven in 2024

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Consensus revenue estimates fall to US$27.8m

Independent Director recently bought US$78k worth of stock

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Consensus forecasts updated

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox